Investigational Studies

Save Article Revive Therapeutics Ltd. (TSXV:RVV), a cannabinoid biopharma stock, jumped after receiving an orphan drug designation for the treatment of autoimmune hepatitis Sean Mason | June 27, 2018 | SmallCapPower A U.S. Food and Drug Administration designation was good news for investors in a cannabinoid biopharma stock Wednesday. Here’s some small stocks making big moves on Wednesday, June […]

by

Epidiolex, GW Pharmaceuticals’ investigational cannabis-based oral therapy, was proven safe in a Phase 2 clinical trial testing it in young children with Dravet syndrome. The therapy is a plant-derived cannabidiol being developed for patients with treatment-resistant forms of epilepsy including Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, and infantile spasms. Data on the Phase 2 CARE1 trial (NCT02091206) were […]

by

-Study did not meet its primary endpoint- -Company remains committed to continued development of GWP42006 for autism spectrum disorders and will continue to explore the product’s potential within the field of epilepsy- LONDON and CARLSBAD, Calif., Feb. 21, 2018 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW,” “the Company” or “the Group”), a biopharmaceutical company […]

by

Treatment with cannabinoids improved muscle function in a mouse model of myasthenia gravis (MG), suggesting they may have therapeutic potential for the disease, researchers say. The study, “Cannabinoid-induced increase of quantal size and enhanced neuromuscular transmission,” appeared in the journal Scientific Reports. Cannabinoids regulate multiple levels of neuronal communication, including the formation of new neurons and the release […]

by

Current first-line therapies for Dravet syndrome have limited effectiveness, but treatment candidates now undergoing clinical testing show significant promise, researchers suggest in a recent review. The study, “Treatment Strategies for Dravet Syndrome,” was published in the journal CNS Drugs. Accurate diagnosis of Dravet syndrome is possible within the first two years of life, when the child […]

by

TORONTO, Sept. 11, 2018 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (TSX VENTURE: RVV) (OTCQB: RVVTF) (FSE: 31R) (“Revive” or the “Company”), a specialty cannabis company focused on the research, development and commercialization of novel cannabinoid-based products, today announced the introduction of RELICANN™, the Company’s hemp-based  and medical cannabis brand designed for the health and wellness […]

by

With the U.S. midterm elections now less than two weeks away, patient advocacy groups are solidly focused on a range of hot-button issues, from the Orphan Drug Tax Credit and affordable health insurance to future funding for rare disease research. Yet “whether Democrats take over the House or Senate, or Republicans stay in control, no […]

by

GW Pharmaceuticals ended 2017 by filing its childhood epilepsy drug Epidiolex with regulators in the US and EU, setting up a potential launch for a drug that could transform the company’s fortunes. Epidiolex (cannabidiol) is expected to become a blockbuster if it is approved in its three major indications. GW specialises in drugs developed from […]

by

MMJ Bio Science has become the first company to obtain a Canadian license to produce medical cannabis, with the initial authorization covering products for multiple sclerosis and Huntington’s disease. The Health Canada license allows the company to extract cannabinoids from plants that it grows to produce therapies that will be tested in U.S. Food and Drug Administration-approved studies. MMJ is pursuing […]

by

SAN DIEGO, Oct. 20, 2017 (GLOBE NEWSWIRE) — Emerald Health Pharmaceuticals Inc. (EHP), which is developing medications based on cannabinoid science, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for its lead molecule, EHP-101, for the treatment of systemic scleroderma. This chronic autoimmune disease causes severe fibrosis of […]

by